---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-128270"
form_type: "8-K"
ticker: "TRDA"
cik: "0001689375"
company_name: "Entrada Therapeutics, Inc."
filed_at: "2022-12-19T23:59:59+00:00"
generated_at: "2026-06-21T02:35:56.337910+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Entrada receives FDA clinical hold on IND for ENTR-601-44 in Duchenne muscular dystrophy

## Summary
- Clinical hold placed on IND for ENTR-601-44, a potential treatment for DMD with exon 44 skippable mutations.
- FDA to provide official clinical hold letter within 30 days; Entrada will work to address concerns.
- No approved therapies exist for patients with exon 44 skippable mutations.
- Entrada plans to share updates after further communications with the FDA.

## SEC filing metadata
- accession: 0001104659-22-128270
- form_type: 8-K
- ticker: TRDA
- cik: 0001689375
- company_name: Entrada Therapeutics, Inc.
- filed_at: 2022-12-19T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1689375/000110465922128270/0001104659-22-128270-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1689375/000110465922128270/tm2233021d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-128270
- JSON: https://secwatch.observer/filing/0001104659-22-128270.json
- Plain text: https://secwatch.observer/filing/0001104659-22-128270.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.